An older female adalt client with myasthenia gravis is concerned about the cost of medications under her Medicare prescription drug plan. She questions the necessity of neostigmine (Prostigmin) and pyrldastigmine bromide (Mestinen). What information is important to provide this client to promote: drug compliance following discharge?
